STOCK WATCH

■ BELGIUM and UK-based Genflow Biosciences, a pioneer in developing anti-ageing drugs, ignored the lure of US markets and listed in London in January, raising £3.7m.

It makes treatments for a healthy long life and is focused on a stress-responsive protein – Sirtuin 6 – researching the role it plays in people who live to 100 and beyond.

Yesterday, it filed patent applications related to the therapeutic uses of the protein and its variants. Shares were flat at 4.75p.